Safety check for promising breast cancer combo
NCT ID NCT04148911
Summary
This study aimed to check the safety of a two-drug combination (atezolizumab plus nab-paclitaxel) for people with a hard-to-treat, advanced form of breast cancer that had spread. It involved 184 participants whose cancer tested positive for a specific marker (PD-L1) and who had not yet received chemotherapy for their advanced disease. The main goal was to monitor for serious side effects while also tracking how long patients lived without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AULSS3 - Presidio di Mirano
Mirano (VE), Veneto, 30035, Italy
-
Ars Medical Sp. z o. o.
Pi?a, 64-920, Poland
-
Azienda Ospedaliera San Giuseppe Moscati
Avellino, Campania, 83100, Italy
-
Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria ? Polo Oncologico
Pisa, Tuscany, 56126, Italy
-
Azienda Universitaria Magna Grecia
Catanzaro, Calabria, 88100, Italy
-
Azienda ospedaliero-universitaria careggi, Sezione di radioterapia del dipartimento di fisiopatolo
Florence, Tuscany, 50134, Italy
-
B-A-Z Vármegyei Központi Kórház és Egyetemi Oktatókórház
Miskolc, 3526, Hungary
-
Bács-Kiskun Vármegyei Oktatókórház
Kecskemét, 6000, Hungary
-
CEMIC
Buenos Aires, C1431FWN, Argentina
-
Centre Leon Berard
Lyon, 69373, France
-
Centrul de Oncologie Sfantul Nectarie
Craiova, 200542, Romania
-
Centrul de Radioterapie AMETHYST
Floreşti, 407280, Romania
-
Clinica Oncologica-Ospedali Riuniti Ancona
Torrette, Tuscany, 60020, Italy
-
Clinique Onco Des Dentellieres
Valenciennes, 59300, France
-
Corporacio Sanitaria Parc Tauli
Sabadell, Barcelona, 08208, Spain
-
Debreceni Egyetem Klinikai Kozpont
Debrecen, 4032, Hungary
-
Departement Medecine
Villejuif, 94805, France
-
Fakultni Poliklinika Vseobecne Fakultni Niemocnice
Prague, 128 08, Czechia
-
Fondazione IRCCS Policlinico San Matteo, Oncologia
Pavia, Lombardy, 27100, Italy
-
Fondazione del Piemonte per l?Oncologia (IRCCS)
Candiolo, Trentino-Alto Adige, 10060, Italy
-
Hospital Alvaro Cunqueiro
Vigo, Pontevedra, 36312, Spain
-
Hospital Clinico Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital Cuf Descobertas
Lisbon, 1998-018, Portugal
-
Hospital Garcia de Orta
Almada, 2801-951, Portugal
-
Hospital General Universitario J.M Morales Meseguer
Murcia, 30008, Spain
-
Hospital General Universitario de Elche
Elche, Alicante, 03203, Spain
-
Hospital Lucus Augusti
Lugo, 27003, Spain
-
Hospital Nacional Cayetano Heredia
Lima, 31, Peru
-
Hospital Univ. Central de Asturias
Oviedo, Principality of Asturias, 33011, Spain
-
Hospital Universitari Arnau de Vilanova de Lleida
Lleida, 25198, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario San Cecilio
Granada, 18003, Spain
-
Hospital de Basurto
Bilbao, Vizcaya, 48013, Spain
-
Hospital de Oncología Siglo XXI
Mexico City, Mexico CITY (federal District), 06720, Mexico
-
Hospital de S. Francisco Xavier
Lisbon, 1495-005, Portugal
-
Hôpital Franco-Britannique- Fondation Cognacq-Jay
Levallois-Perret, 92300, France
-
IPO de Coimbra
Coimbra, 3000-075, Portugal
-
IPO de Lisboa
Lisbon, 1099-023, Portugal
-
IPO do Porto
Porto, 4200-072, Portugal
-
Institut de Cancérologie de Bourgogne
Dijon, 21000, France
-
Institut de cancerologie du Gard
Nîmes, 30029, France
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
-
Instituto Nacional de Cancerologia
Distrito Federal, 14080, Mexico
-
Instituto Nacional de Enfermedades Neoplasicas
Lima, 15038, Peru
-
Instituto de Radiomedicina, IRAM
Santiago, 7630370, Chile
-
Irccs Ospedale San Raffaele
Milan, Lombardy, 20132, Italy
-
Istituto Europeo Di Oncologia
Milan, Lombardy, 20141, Italy
-
Komarom-Eszergom Varmegyei Szent Borbala Korhaz
Tatabánya, 2800, Hungary
-
MRUKMED Lekarz Beata Madej-Mruk i Partner Spolka Partnerska Oddzial nr 1 w Rzeszowie
Rzeszów, 35-021, Poland
-
Nemocnice AGEL Novy Jicin a.s.
Nový Jičín, 741 01, Czechia
-
Nemocnice na Bulovce
Prague, 180 81, Czechia
-
Nuovo Ospedale di Prato S. Stefano - Azienda USL Toscana Centro
Prato, Tuscany, 59100, Italy
-
Organizacion Medica de Investigacion
San Nicolás, C1015ABO, Argentina
-
Ospedale Cannizzaro, Oncologia
Catania, Sicily, 95126, Italy
-
Ospedale Civile
Sassari, Sardinia, 07100, Italy
-
Ospedale San Gerardo
Monza, Lombardy, 20900, Italy
-
Ospedale Santa Chiara
Trento, Trentino-Alto Adige, 38100, Italy
-
Policlinico Universitario Agostino Gemelli
Rome, Lazio, 00168, Italy
-
Pontificia Universidad Catolica de Chile
Santiago, Chile
-
Prof. Dr. I. Chiricuta Institute of Oncology
Cluj-Napoca, 400015, Romania
-
Sanatorio de la Mujer
Rosario, S2000ORE, Argentina
-
Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny
Brzozów, 36-200, Poland
-
Szpital Wojewódzki im. Miko?aja Kopernika
Koszalin, 75-581, Poland
-
USL Umbria 1 - Osp. Città di Castello
Città Di Castello (PG), Umbria, 06012, Italy
-
Univerzitetni klini?ni center Maribor
Maribor, 2000, Slovenia
-
Zala Vármegyei Szent Rafael Kórház
Zalaegerszeg, 8900, Hungary
Conditions
Explore the condition pages connected to this study.